Natalie Galanina

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim et al. · Nature Communications · 2020 · 302 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL

Sabah Kadri, Jimmy Lee, Carrie Fitzpatrick et al. · Blood Advances · 2017 · 132 citations · Full text

Medicine, Genetics, Oncology +17

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade

Natalie Galanina, Aaron M. Goodman, Philip R Cohen et al. · Cancer Immunology Research · 2018 · 115 citations · Full text

Medicine, Immunology, Oncology +17

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL

Shruti Sharma, Natalie Galanina, Ailin Guo et al. · Oncotarget · 2016 · 89 citations · Full text

Medicine, Molecular Biology, Oncology +16

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Jimmy Lee, Liang Leo Zhang, Wenjun Wu et al. · Blood Advances · 2018 · 62 citations · Full text

Medicine, Cancer Biology, Oncology +13